P709: Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysisECCO '18 Vienna
2018
P710: Efficacy of therapeutic intervention for ulcerative colitis patients with the Mayo Endoscopic Score of 1ECCO '18 Vienna
2018
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of responseECCO '18 Vienna
2018
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modellingECCO '18 Vienna
2018
P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusionsECCO '18 Vienna
2018
P714: Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patientsECCO '18 Vienna
2018
P717: Comparison of two different techniques to assess vedolizumab trough levels in adult patients with IBDECCO '18 Vienna
2018
P718: Discrepancies between patients’ preferences and physicians’ preference perception for oral formulations: A real-life surveyECCO '18 Vienna
2018
P719: Does radiation to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative studyECCO '18 Vienna
2018
P720: Is there a difference in trough levels and immunogenicity between Crohn’s disease and ulcerative colitis patients treated with infliximab?ECCO '18 Vienna
2018
P721: Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine careECCO '18 Vienna
2018
P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBDECCO '18 Vienna
2018
P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)ECCO '18 Vienna
2018